| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 34 | 2022 | 1797 | 4.890 |
Why?
|
| Brain Neoplasms | 50 | 2023 | 4849 | 4.510 |
Why?
|
| Magnetic Resonance Imaging | 43 | 2024 | 7702 | 3.590 |
Why?
|
| Genomics | 17 | 2021 | 2738 | 2.490 |
Why?
|
| Molecular Imaging | 6 | 2018 | 185 | 1.380 |
Why?
|
| Speech | 2 | 2017 | 133 | 1.050 |
Why?
|
| Glioma | 8 | 2023 | 1963 | 1.030 |
Why?
|
| Diagnostic Imaging | 6 | 2021 | 1162 | 1.010 |
Why?
|
| Neuroimaging | 4 | 2023 | 403 | 0.980 |
Why?
|
| Immunotherapy | 7 | 2024 | 3341 | 0.920 |
Why?
|
| Rare Diseases | 4 | 2022 | 351 | 0.870 |
Why?
|
| Brain Mapping | 4 | 2020 | 644 | 0.810 |
Why?
|
| Image Interpretation, Computer-Assisted | 10 | 2018 | 592 | 0.770 |
Why?
|
| Cordotomy | 1 | 2020 | 46 | 0.710 |
Why?
|
| Neuronavigation | 1 | 2019 | 47 | 0.700 |
Why?
|
| Brain | 10 | 2022 | 4113 | 0.680 |
Why?
|
| Language | 2 | 2020 | 309 | 0.670 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2022 | 1648 | 0.660 |
Why?
|
| Pain, Intractable | 1 | 2020 | 171 | 0.650 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 361 | 0.640 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.630 |
Why?
|
| Extracorporeal Shockwave Therapy | 1 | 2017 | 6 | 0.630 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2019 | 502 | 0.610 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 341 | 0.600 |
Why?
|
| Neoplasms | 9 | 2021 | 15193 | 0.600 |
Why?
|
| Pneumonia | 2 | 2017 | 751 | 0.590 |
Why?
|
| Endpoint Determination | 2 | 2017 | 176 | 0.580 |
Why?
|
| Humans | 101 | 2024 | 261506 | 0.580 |
Why?
|
| World Health Organization | 2 | 2023 | 316 | 0.570 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 96 | 0.570 |
Why?
|
| Essential Tremor | 1 | 2017 | 85 | 0.570 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2021 | 160 | 0.550 |
Why?
|
| Retrospective Studies | 26 | 2023 | 37905 | 0.540 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 577 | 0.530 |
Why?
|
| Laser Therapy | 1 | 2019 | 411 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2021 | 7551 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.490 |
Why?
|
| Aged | 41 | 2021 | 70117 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 3251 | 0.460 |
Why?
|
| Middle Aged | 41 | 2021 | 86204 | 0.460 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 510 | 0.440 |
Why?
|
| Neurosurgery | 2 | 2010 | 108 | 0.430 |
Why?
|
| Adult | 35 | 2023 | 77950 | 0.430 |
Why?
|
| Male | 54 | 2021 | 123000 | 0.430 |
Why?
|
| Cell Death | 1 | 2014 | 671 | 0.420 |
Why?
|
| Young Adult | 15 | 2021 | 21445 | 0.390 |
Why?
|
| Biomarkers, Tumor | 11 | 2024 | 10331 | 0.390 |
Why?
|
| Extracellular Vesicles | 2 | 2024 | 135 | 0.390 |
Why?
|
| Gene Expression | 2 | 2018 | 3570 | 0.380 |
Why?
|
| Ultrasonic Therapy | 1 | 2010 | 55 | 0.370 |
Why?
|
| Genetic Testing | 3 | 2017 | 1589 | 0.370 |
Why?
|
| Female | 53 | 2021 | 141928 | 0.360 |
Why?
|
| Radiation Injuries | 2 | 2016 | 1411 | 0.360 |
Why?
|
| Edema | 1 | 2011 | 267 | 0.350 |
Why?
|
| RNA, Neoplasm | 1 | 2012 | 771 | 0.350 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 4892 | 0.340 |
Why?
|
| Phenotype | 6 | 2017 | 6295 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1258 | 0.340 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 29902 | 0.330 |
Why?
|
| Spinal Cord Diseases | 2 | 2024 | 90 | 0.320 |
Why?
|
| Proportional Hazards Models | 9 | 2023 | 4988 | 0.320 |
Why?
|
| Area Under Curve | 5 | 2020 | 700 | 0.320 |
Why?
|
| Algorithms | 7 | 2022 | 3890 | 0.310 |
Why?
|
| Transcriptome | 1 | 2016 | 1859 | 0.310 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 7222 | 0.310 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2007 | 7 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 429 | 0.300 |
Why?
|
| Precision Medicine | 4 | 2020 | 1154 | 0.300 |
Why?
|
| Hyalin | 1 | 2007 | 17 | 0.300 |
Why?
|
| Image Enhancement | 4 | 2018 | 561 | 0.300 |
Why?
|
| Immunocompetence | 1 | 2007 | 75 | 0.290 |
Why?
|
| Survival Analysis | 10 | 2017 | 9180 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 383 | 0.290 |
Why?
|
| Cryptococcosis | 1 | 2007 | 63 | 0.290 |
Why?
|
| Contrast Media | 6 | 2018 | 1472 | 0.290 |
Why?
|
| Sensitivity and Specificity | 11 | 2019 | 4971 | 0.280 |
Why?
|
| Positron-Emission Tomography | 7 | 2021 | 2173 | 0.280 |
Why?
|
| Lung Diseases, Fungal | 1 | 2007 | 124 | 0.280 |
Why?
|
| MicroRNAs | 4 | 2015 | 2947 | 0.270 |
Why?
|
| Genome, Human | 1 | 2014 | 1869 | 0.270 |
Why?
|
| Prognosis | 16 | 2023 | 21713 | 0.260 |
Why?
|
| Disease Progression | 5 | 2021 | 6682 | 0.260 |
Why?
|
| Adolescent | 12 | 2020 | 31252 | 0.250 |
Why?
|
| Bevacizumab | 3 | 2017 | 938 | 0.250 |
Why?
|
| Spondylosis | 1 | 2024 | 5 | 0.240 |
Why?
|
| DNA Modification Methylases | 2 | 2016 | 172 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 6207 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2020 | 5437 | 0.240 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2292 | 0.230 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2023 | 15 | 0.230 |
Why?
|
| Radiography | 5 | 2015 | 1904 | 0.230 |
Why?
|
| DNA Repair Enzymes | 2 | 2016 | 237 | 0.230 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 14289 | 0.220 |
Why?
|
| Dexamethasone | 2 | 2018 | 1450 | 0.220 |
Why?
|
| Treatment Outcome | 14 | 2024 | 32848 | 0.220 |
Why?
|
| Hydrazines | 2 | 2021 | 208 | 0.220 |
Why?
|
| Encephalitis | 1 | 2023 | 143 | 0.210 |
Why?
|
| Genetic Markers | 4 | 2017 | 974 | 0.200 |
Why?
|
| Genes, erbB | 1 | 2021 | 26 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3821 | 0.200 |
Why?
|
| Esophageal Neoplasms | 7 | 2009 | 3168 | 0.200 |
Why?
|
| Information Dissemination | 2 | 2022 | 272 | 0.200 |
Why?
|
| Lung Diseases | 1 | 2007 | 717 | 0.190 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 4053 | 0.190 |
Why?
|
| Radiopharmaceuticals | 5 | 2021 | 1301 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5319 | 0.190 |
Why?
|
| Interinstitutional Relations | 1 | 2020 | 37 | 0.190 |
Why?
|
| Skull | 1 | 2022 | 231 | 0.190 |
Why?
|
| Preoperative Period | 2 | 2020 | 344 | 0.190 |
Why?
|
| Privacy | 1 | 2020 | 34 | 0.180 |
Why?
|
| Lomustine | 2 | 2017 | 39 | 0.180 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 11538 | 0.180 |
Why?
|
| Karyopherins | 1 | 2021 | 136 | 0.180 |
Why?
|
| Triazoles | 2 | 2021 | 617 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 624 | 0.180 |
Why?
|
| Support Vector Machine | 1 | 2019 | 44 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 4 | 2015 | 3976 | 0.170 |
Why?
|
| Reproducibility of Results | 8 | 2017 | 6009 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2021 | 235 | 0.160 |
Why?
|
| Medicine | 1 | 2020 | 137 | 0.160 |
Why?
|
| Postoperative Care | 3 | 2018 | 739 | 0.160 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 1910 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 665 | 0.160 |
Why?
|
| Ependymoma | 1 | 2020 | 242 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 245 | 0.160 |
Why?
|
| Tomography, Emission-Computed | 2 | 2009 | 310 | 0.160 |
Why?
|
| Thy-1 Antigens | 1 | 2017 | 51 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 524 | 0.150 |
Why?
|
| Vomiting | 2 | 2021 | 354 | 0.150 |
Why?
|
| Microscopy, Polarization | 1 | 2016 | 9 | 0.150 |
Why?
|
| Nausea | 2 | 2021 | 525 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2023 | 732 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2017 | 649 | 0.150 |
Why?
|
| Learning | 1 | 2020 | 403 | 0.150 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 10001 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 1823 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 591 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2015 | 925 | 0.140 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2015 | 1105 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 992 | 0.140 |
Why?
|
| Functional Laterality | 1 | 2017 | 316 | 0.140 |
Why?
|
| Survival Rate | 9 | 2020 | 12221 | 0.140 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 36 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 665 | 0.140 |
Why?
|
| Lung | 1 | 2007 | 3151 | 0.130 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 434 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 187 | 0.130 |
Why?
|
| Medulloblastoma | 1 | 2020 | 540 | 0.130 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2015 | 123 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 904 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2021 | 6869 | 0.130 |
Why?
|
| Ependyma | 1 | 2014 | 13 | 0.130 |
Why?
|
| Patient Selection | 2 | 2021 | 2055 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2016 | 2669 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 403 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2017 | 1987 | 0.120 |
Why?
|
| ROC Curve | 2 | 2015 | 1183 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2283 | 0.120 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 478 | 0.120 |
Why?
|
| Animals | 9 | 2021 | 59536 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 2104 | 0.120 |
Why?
|
| Brain Edema | 1 | 2014 | 86 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2017 | 2803 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2024 | 12873 | 0.120 |
Why?
|
| Biomarkers | 3 | 2024 | 5047 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 323 | 0.110 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.110 |
Why?
|
| Mice | 7 | 2021 | 34495 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 195 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 615 | 0.110 |
Why?
|
| Logistic Models | 3 | 2016 | 3441 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 171 | 0.110 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 4844 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2009 | 1226 | 0.110 |
Why?
|
| Forecasting | 2 | 2018 | 694 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2020 | 2218 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1656 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 580 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 304 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 447 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 840 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2016 | 554 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2020 | 1423 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 3981 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.100 |
Why?
|
| Organs at Risk | 1 | 2014 | 514 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2330 | 0.100 |
Why?
|
| Spinal Diseases | 1 | 2012 | 125 | 0.100 |
Why?
|
| Vertebroplasty | 1 | 2011 | 24 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 1533 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2015 | 1090 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2011 | 42 | 0.090 |
Why?
|
| Aortography | 1 | 2011 | 181 | 0.090 |
Why?
|
| Risk Factors | 5 | 2021 | 17523 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 186 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 585 | 0.090 |
Why?
|
| Stereotaxic Techniques | 1 | 2010 | 172 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 10035 | 0.090 |
Why?
|
| Cell Movement | 1 | 2017 | 2466 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 15862 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 245 | 0.090 |
Why?
|
| Spinal Fractures | 1 | 2011 | 132 | 0.090 |
Why?
|
| Cerebral Angiography | 1 | 2010 | 129 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 162 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3101 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 2139 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2011 | 153 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 2265 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2010 | 123 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 8865 | 0.080 |
Why?
|
| Liposomes | 1 | 2010 | 684 | 0.080 |
Why?
|
| Embolization, Therapeutic | 2 | 2011 | 551 | 0.080 |
Why?
|
| Software | 2 | 2014 | 1321 | 0.080 |
Why?
|
| Melanoma | 2 | 2023 | 5317 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2008 | 141 | 0.080 |
Why?
|
| Esophageal Diseases | 1 | 2008 | 69 | 0.080 |
Why?
|
| Cytokines | 1 | 2016 | 2809 | 0.070 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.070 |
Why?
|
| Time Factors | 1 | 2021 | 12926 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2011 | 384 | 0.070 |
Why?
|
| Europe | 2 | 2023 | 649 | 0.070 |
Why?
|
| Mutation | 4 | 2023 | 15179 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2134 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8873 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2008 | 193 | 0.070 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 1022 | 0.070 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 7789 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4757 | 0.070 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.060 |
Why?
|
| Multimodal Imaging | 2 | 2021 | 550 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2014 | 1330 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4367 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 5159 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 846 | 0.060 |
Why?
|
| Dyspnea | 1 | 2007 | 416 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2027 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 726 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2024 | 205 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1053 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 121 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2021 | 2295 | 0.050 |
Why?
|
| Carcinoma | 2 | 2016 | 2578 | 0.050 |
Why?
|
| Zirconium | 1 | 2021 | 6 | 0.050 |
Why?
|
| Lutetium | 1 | 2021 | 6 | 0.050 |
Why?
|
| Radiology | 2 | 2017 | 434 | 0.050 |
Why?
|
| Infusions, Intraventricular | 1 | 2020 | 29 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2021 | 177 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 4938 | 0.050 |
Why?
|
| Topotecan | 1 | 2021 | 239 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 323 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 319 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 2864 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2014 | 5270 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 1443 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3552 | 0.040 |
Why?
|
| United States | 4 | 2023 | 15433 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2015 | 11965 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 14889 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14551 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 480 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4557 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 823 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1163 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5539 | 0.040 |
Why?
|
| Child | 2 | 2020 | 29154 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 1216 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 50 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 175 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 28 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 41 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 334 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 388 | 0.030 |
Why?
|
| DNA Repair | 1 | 2004 | 1872 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 284 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1052 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5178 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2011 | 5542 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 2231 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 355 | 0.030 |
Why?
|
| Anilides | 1 | 2017 | 268 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 193 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 143 | 0.030 |
Why?
|
| Uveal Neoplasms | 1 | 2016 | 176 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2021 | 1996 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 256 | 0.030 |
Why?
|
| Exanthema | 1 | 2016 | 211 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 544 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 327 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.030 |
Why?
|
| Esophagectomy | 2 | 2008 | 911 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 497 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1331 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2009 | 13658 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 73 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 445 | 0.030 |
Why?
|
| Benchmarking | 1 | 2014 | 273 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 2049 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 1144 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 923 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 172 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Spin Labels | 1 | 2012 | 76 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2015 | 624 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4744 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 1555 | 0.030 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2011 | 22 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2170 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 3 | 2008 | 4975 | 0.020 |
Why?
|
| Bone Cements | 1 | 2011 | 45 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2011 | 41 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 2927 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 689 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1130 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2017 | 3536 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.020 |
Why?
|
| Women | 1 | 2010 | 27 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Pyridines | 1 | 2017 | 1244 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3033 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1248 | 0.020 |
Why?
|
| Stem Cells | 1 | 2017 | 1213 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 5112 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 1382 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 471 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 1000 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1529 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 4109 | 0.020 |
Why?
|
| Massachusetts | 1 | 2009 | 106 | 0.020 |
Why?
|
| Certification | 1 | 2010 | 123 | 0.020 |
Why?
|
| Workload | 1 | 2010 | 198 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 935 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4307 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 3842 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 609 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.020 |
Why?
|
| Esophagitis | 1 | 2008 | 202 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 5637 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 980 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 4638 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2009 | 543 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 1546 | 0.020 |
Why?
|
| Curriculum | 1 | 2010 | 860 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 2326 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 445 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 3022 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 7591 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2008 | 1529 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 1058 | 0.010 |
Why?
|
| Cisplatin | 1 | 2008 | 2432 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3890 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 15694 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2010 | 1375 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2004 | 1234 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6100 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 5687 | 0.010 |
Why?
|